Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Announces Warrant Exercise
Ablynx NV (Ablynx) announced that an additional 61,812 common shares have been issued by the Company in exchange for EUR 329,619.51 as the result of the exercise of warrants by some employees and consultants of the Company. As a result of this transaction, Ablynx has 43,779,197 shares outstanding.
Latest Developments for Ablynx NV
Latest Key Developments in Biotechnology
- Leaf Energy Ltd announces issue of ordinary shares
- Puma Biotechnology Inc announces positive top line results from Phase III PB272 trial in Adjuvant Breast Cancer (ExteNET Trial)
- Galmed Pharmaceuticals Ltd announces FDA clearance of IND of armachol for treatment of fatty liver disorders
- CEL-SCI Corp receives regulatory clearance to expand phase III head and neck cancer trial into Turkey
- Share this
- Digg this